Would you use perioperative durvalumab in patients with diffuse-type gastric adenocarcinoma given no event-free survival benefit was seen for these patients in MATTERHORN?  

I interpret subgroup analyses with a significant grain of salt. When I see a lack of benefit in a subgroup compared to a significant benefit in the overall population, I ask the question: What is different about this subgroup in the control arm versus the experimental arm? This question is sometimes...